These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 36883603)
41. Biological therapies in children with rheumatic diseases during the COVID-19 pandemic: A single-centre experience. Aydın F; Kurt T; Sezer M; Tekgöz N; Ekici Tekin Z; Kanık Yüksek S; Çelikel Acar B Int J Clin Pract; 2021 Jul; 75(7):e14030. PubMed ID: 34233400 [No Abstract] [Full Text] [Related]
42. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis Schulze-Koops H; Krueger K; Specker C Ann Rheum Dis; 2021 Apr; 80(4):e61. PubMed ID: 32475833 [No Abstract] [Full Text] [Related]
43. Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Kearsley-Fleet L; Chang ML; Lawson-Tovey S; Costello R; Fingerhutová Š; Švestková N; Belot A; Aeschlimann FA; Melki I; Koné-Paut I; Eulert S; Kallinich T; Berkun Y; Uziel Y; Raffeiner B; Oliveira Ramos F; Clemente D; Dackhammar C; Wulffraat NM; Waite H; Strangfeld A; Mateus EF; Machado PM; ; ; Natter M; Hyrich KL Ann Rheum Dis; 2022 Jul; 81(7):998-1005. PubMed ID: 35338032 [TBL] [Abstract][Full Text] [Related]
45. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Chopra A; Abdel-Nasser A Best Pract Res Clin Rheumatol; 2008 Aug; 22(4):583-604. PubMed ID: 18783739 [TBL] [Abstract][Full Text] [Related]
46. Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'. Ruyssen-Witrand A; Soubrier M; Basch A; Truchetet ME; Seror R Ann Rheum Dis; 2023 Feb; 82(2):e32. PubMed ID: 33177101 [No Abstract] [Full Text] [Related]
47. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Tam LS; Tanaka Y; Handa R; Chang CC; Cheng YK; Isalm N; Li M; Lorenzo JP; Song YW; Yamamoto K; Zeng X; Haq SA Int J Rheum Dis; 2020 Jun; 23(6):717-722. PubMed ID: 32462761 [No Abstract] [Full Text] [Related]
48. Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands. Bos WH; van Tubergen A; Vonkeman HE Rheumatol Int; 2021 Mar; 41(3):565-573. PubMed ID: 33449162 [TBL] [Abstract][Full Text] [Related]
49. The impact of the ongoing COVID-19 pandemic on the management of rheumatic disease: a national clinician-based survey. Kahveci A; Gümüştepe A; Güven N; Ataman Ş Rheumatol Int; 2022 Apr; 42(4):601-608. PubMed ID: 35165770 [TBL] [Abstract][Full Text] [Related]
50. Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience. Pineda-Sic RA; Galarza-Delgado DA; Serna-Peña G; Castillo-Torres SA; Flores-Alvarado DE; Esquivel-Valerio JA; Hernández-Galarza IJ Ann Rheum Dis; 2021 Jun; 80(6):e85. PubMed ID: 32576568 [No Abstract] [Full Text] [Related]
51. Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand Ciurea A; Finckh A Ann Rheum Dis; 2023 Feb; 82(2):e33. PubMed ID: 33177100 [No Abstract] [Full Text] [Related]
52. Genetic predisposition between coronavirus disease 2019 and rheumatic diseases: A 2-sample Mendelian randomization study. Quan L; Tan J; Hua L; You X Int J Rheum Dis; 2023 Apr; 26(4):710-717. PubMed ID: 36890668 [TBL] [Abstract][Full Text] [Related]
53. Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. Gupta L; Misra DP; Agarwal V; Balan S; Agarwal V Ann Rheum Dis; 2021 Jan; 80(1):e1. PubMed ID: 32299795 [No Abstract] [Full Text] [Related]
54. Pseudoscience at the expense of rheumatic disease patients during the Coronavirus disease 2019 pandemic. Akkoc N Clin Exp Rheumatol; 2021; 39 Suppl 128(1):5-7. PubMed ID: 32662406 [No Abstract] [Full Text] [Related]
55. [Not Available]. Strangfeld A Drug Res (Stuttg); 2015 Nov; 65 Suppl 1():S3-4. PubMed ID: 26536188 [No Abstract] [Full Text] [Related]
56. The Disparities in Patient Portal Use Among Patients With Rheumatic and Musculoskeletal Diseases: Retrospective Cross-sectional Study. Sun EY; Alvarez C; Callahan LF; Sheikh SZ J Med Internet Res; 2022 Aug; 24(8):e38802. PubMed ID: 36001872 [TBL] [Abstract][Full Text] [Related]
57. Increasing autoimmune rheumatic diseases as a consequence of the COVID-19 pandemic: A hypothesis or fact? Baimukhamedov C; Togizbayev G; Mirakhmedova K; Mamasaidov A; Shukurova S Int J Rheum Dis; 2024 Jan; 27(1):e15011. PubMed ID: 38140787 [No Abstract] [Full Text] [Related]
58. Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease. Robinson PC; Kim AHJ Best Pract Res Clin Rheumatol; 2021 Mar; 35(1):101664. PubMed ID: 33610466 [No Abstract] [Full Text] [Related]
59. Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Karaarslan F; Güneri FD; Kardeş S Clin Rheumatol; 2022 Jan; 41(1):289-296. PubMed ID: 34713356 [TBL] [Abstract][Full Text] [Related]
60. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic Schulze-Koops H; Krueger K; Specker C; Ann Rheum Dis; 2021 Jun; 80(6):e86. PubMed ID: 32576567 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]